RCC study

Tom Powles: Annual meeting of the CARE 1 metastatic 1st line RCC study

Tom Powles, Director of Barts Cancer Center, shared a post on X:

“Annual meeting of the CARE 1 metastatic 1st line RCC study which is open in France and will open in UK soon.

Biomarker driven trial (PD-L1) of ipi/nivo versus VEGF/PD1. 

The Barts team in Paris enjoying the sunshine!”
RCC study
Source: Tom Powles/X
Barts Cancer Center cancer OncoDaily Oncology PD-L1 RCC study Tom Powles VEGF/PD1